FGFR3, fibroblast growth factor receptor 3, 2261

N. diseases: 654; N. variants: 55
Disease: Multiple Myeloma ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.700 AlteredExpression disease BEFREE 14.5% (16/110) of MM BM samples showed dysregulated FGFR3 expression. 12028033 2002
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.700 GeneticVariation disease BEFREE The karyotypically silent t(4;14)(p16.3;q32) translocation can be found in approximately 15-20% of multiple myeloma (MM) patients and results in the ectopic expression of fibroblast growth factor receptor 3 (FGFR3) from der4. 12368157 2002
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.700 CausalMutation disease CGI
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.700 AlteredExpression disease BEFREE The presence of switch translocations was supported by demonstrating up-regulated expression in myeloma marrow of cyclin D1 and fibroblast growth factor receptor 3 (FGFR3), candidate oncogenes on chromosomes 11q13 and 4p16, respectively. 11154227 2001
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.700 AlteredExpression disease BEFREE Approximately 15% of patients with multiple myeloma (MM) exhibit a t(4;14) translocation, which often results in constitutive activation of the receptor tyrosine kinase (RTK) fibroblast growth factor receptor 3 (FGFR3). 25402977 2015
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.700 Biomarker disease BEFREE Ribosomal protein metallopanstimulin-1 impairs multiple myeloma CAG cells growth and inhibits fibroblast growth factor receptor 3. 21889435 2011
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.700 GeneticVariation disease BEFREE Our data indicates that Y373C mutation and wild-type FGFR3 may be associated with bortezomib-related treatment resistance in multiple myeloma. 19331127 2009
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.700 AlteredExpression disease BEFREE These data suggest that an endogenous negative regulatory role for the p85-FGFR3 interaction on the Ras/ERK/MAPK pathway may exist in response to FGFR3 activity and identifies a novel therapeutic target for MM. 19286672 2009
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.700 PosttranslationalModification disease BEFREE SU5402 inhibited FGFR3 phosphorylation in vitro and in murine MM tumour models. 14871245 2004
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.700 CausalMutation disease CLINVAR
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.700 Biomarker disease BEFREE Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. 19381019 2009
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.700 AlteredExpression disease BEFREE This suggests that dysregulated FGFR3 expression is likely to be essential at least for the early stages of pathogenesis of MM tumors that have a t(4;14) translocation. 20393505 2010
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.700 Biomarker disease BEFREE There is a promiscuous array of nonrandom chromosomal partners (and oncogenes), with the 3 most frequent partners (11q13 [cyclin D1]; 4p16 [FGFR3 and MMSET]; 16q23 [c-maf]) involved in nearly half of MM tumors. 11418483 2001
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.700 AlteredExpression disease BEFREE As the expression of FGFR3 is undetectable in 30% of the t(4;14)+ MM patients, MMSET has been suggested to play an important role in the malignant transformation associated with the t(4;14) translocation. 16115125 2005
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.700 GeneticVariation disease BEFREE The ectopically expressed fibroblast growth factor receptor 3 (FGFR3) and its constitutively active mutations have been detected in patients with multiple myeloma (MM). 21273588 2011
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.700 GeneticVariation disease CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011 2016
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.700 GeneticVariation disease BEFREE Nearly 40% of MM tumors have immunoglobulin H (IgH) translocations involving four recurrent chromosomal loci (oncogenes): 11q13 (cyclin D1), 6p21 (cyclin D3), 4p16 (MMSET and FGFR3), and 16q23 (c-maf). 12846810 2003
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.700 GeneticVariation disease LHGDN We investigated the presence of FGFR3 expression and activating mutations in a series of newly diagnosed MM patients. 12368157 2002
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.700 Biomarker disease BEFREE The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. 11290605 2001
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.700 AlteredExpression disease BEFREE Three short hairpin RNAs (shRNA) targeting different sites of FGFR3 were selected and subsequently transfected into KMS-11, OPM-2, and NCI-H929 human myeloma cell lines, all of which are characterized by t(4;14) and FGFR3 over expression. 15897243 2005
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.700 Biomarker disease BEFREE To dissect the mechanism of FGFR3 oncogenesis in MM, we used 3 FGFR selective kinase inhibitors-CHIR258, PD173074, and SU5402-and FGFR3-specific siRNA to modulate FGFR3 activity. 16849642 2006
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.700 GeneticVariation disease BEFREE Recently, activating FGFR3 mutations have also been found to be present in cancer, i.e. at high frequency in carcinoma of the bladder and rarely in multiple myeloma and carcinoma of the cervix. 12461689 2002
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.700 GeneticVariation disease BEFREE Since cell lines may represent useful models for investigating the effects of deregulated FGFR3 mutants in MM, we analysed the expression, activation, signaling pathways and oncogenic potential of three mutants identified so far: the Y373C and K650E in the KMS-11 and OPM-2 cell lines respectively, and the novel G384D mutation here identified in the KMS-18 cell line. 11429702 2001
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.700 Biomarker disease LHGDN Ribozyme cleavage leads to decreased expression of fibroblast growth factor receptor 3 in human multiple myeloma cells, which is associated with apoptosis and downregulation of vascular endothelial growth factor. 15788896 2005
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.700 Biomarker disease BEFREE A t(4;14)/IGH-FGFR3 was detected in 28 PCM (11.1%) and 5 MGUS (1.9%; P < 0.001). 21156229 2010